Scholarlink

Background <p>Multiple sclerosis (MS) is a chronic demyelinating disorder of the central nervous system (CNS) characterized by persistent neuroinflammation and immune cell infiltration. Despite extensive study, the specific mechanisms by which local microenvironmental signals enable peripheral immune cells to breach the blood-brain barrier (BBB)—especially without overt structural disruption—are not fully understood.</p> Methods <p>We utilized integrated transcriptomic analysis to identify specific microglia populations in demyelinating lesions. In vitro cellular models, coupled with confocal microscopy and biochemical analyses, were employed to investigate the interaction between microglia-derived factors and vascular endothelial cells, specifically evaluating adhesion molecule dynamics and transendothelial migration. In vivo validation was performed using an experimental autoimmune encephalomyelitis (EAE) mouse model to assess the effects of targeted pharmacological inhibition on immune cell infiltration and clinical disease severity.</p> Results <p>We identified a distinct MS-inflamed microglia (MIMS) population characterized by high expression of secreted phosphoprotein 1 (SPP1, osteopontin), which is markedly increased in chronic lesions. Integrated transcriptomic and in vitro experiments revealed that microglial SPP1 acts on endothelial cells via an interaction with the Integrin αVβ1 (ITGAV/ITGB1) receptor complex. Mechanistically, this engagement activates the Focal Adhesion Kinase (FAK)/NF-κB signaling cascade, driving the robust expression and dynamic turnover of endothelial adhesion molecules. Crucially, this SPP1-driven endothelial activation enables the massive, pan-lineage recruitment of circulating immune cells without evidence of overt barrier disruption. Furthermore, in vivo intrathecal inhibition of SPP1 significantly reduced peripheral immune cell migration into the CNS and alleviated disease severity in the EAE model.</p> Conclusions <p>CNS-resident microglia actively instruct the vascular endothelium via the SPP1-ITGAV-FAK axis to orchestrate peripheral immune cell entry without overt barrier disruption. These findings provide insights into neuro-immune crosstalk at the BBB and highlight a potential targetable pathway for modifying compartmentalized neuroinflammatory diseases.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Blocking the microglia-endothelial axis via SPP1-ITGAV disruption attenuates neuroinflammation in multiple sclerosis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月29日

查看全文
  • Xia Xiao,
  • Shishi Shen,
  • Tingting Cui,
  • Hanzhang Tan,
  • Shengfei Hu,
  • Xia Deng,
  • Yiying Huang,
  • Chunping Cui,
  • Boguang Yu,
  • Wei Qiu,
  • Liang Gao,
  • Yipeng Zhao

摘要

Background

Multiple sclerosis (MS) is a chronic demyelinating disorder of the central nervous system (CNS) characterized by persistent neuroinflammation and immune cell infiltration. Despite extensive study, the specific mechanisms by which local microenvironmental signals enable peripheral immune cells to breach the blood-brain barrier (BBB)—especially without overt structural disruption—are not fully understood.

Methods

We utilized integrated transcriptomic analysis to identify specific microglia populations in demyelinating lesions. In vitro cellular models, coupled with confocal microscopy and biochemical analyses, were employed to investigate the interaction between microglia-derived factors and vascular endothelial cells, specifically evaluating adhesion molecule dynamics and transendothelial migration. In vivo validation was performed using an experimental autoimmune encephalomyelitis (EAE) mouse model to assess the effects of targeted pharmacological inhibition on immune cell infiltration and clinical disease severity.

Results

We identified a distinct MS-inflamed microglia (MIMS) population characterized by high expression of secreted phosphoprotein 1 (SPP1, osteopontin), which is markedly increased in chronic lesions. Integrated transcriptomic and in vitro experiments revealed that microglial SPP1 acts on endothelial cells via an interaction with the Integrin αVβ1 (ITGAV/ITGB1) receptor complex. Mechanistically, this engagement activates the Focal Adhesion Kinase (FAK)/NF-κB signaling cascade, driving the robust expression and dynamic turnover of endothelial adhesion molecules. Crucially, this SPP1-driven endothelial activation enables the massive, pan-lineage recruitment of circulating immune cells without evidence of overt barrier disruption. Furthermore, in vivo intrathecal inhibition of SPP1 significantly reduced peripheral immune cell migration into the CNS and alleviated disease severity in the EAE model.

Conclusions

CNS-resident microglia actively instruct the vascular endothelium via the SPP1-ITGAV-FAK axis to orchestrate peripheral immune cell entry without overt barrier disruption. These findings provide insights into neuro-immune crosstalk at the BBB and highlight a potential targetable pathway for modifying compartmentalized neuroinflammatory diseases.